You don't always have to fix the broken thing. Sometimes you just have to move it.
Within the nucleus of every human cell, genes do not merely exist — they occupy positions that shape whether they speak or stay silent. Researchers at the University of Pennsylvania have now shown that this spatial logic is not fixed fate but a continuous negotiation between transcription and a protein called cohesin, functioning together like a dimmer on the light of gene expression. In Friedreich's ataxia, a devastating neurological disease, this balance is broken — the gene responsible for producing a critical protein drifts to the nucleus's silencing edge — but the discovery that reducing cohesin can coax it back toward activity opens a door to therapies that treat not the mutation itself, but the architecture surrounding it.
- A long-standing mystery in cell biology — whether a gene's location controls its activity or the reverse — has been resolved: the answer is both, operating in constant mutual adjustment.
- In Friedreich's ataxia patients, the FXN gene is pushed to the nuclear periphery where it falls silent, depriving the body of frataxin protein and triggering irreversible neurological and cardiac damage.
- Using CRISPR tools, researchers demonstrated they could reposition genes by tuning transcription and cohesin levels, revealing the nucleus as a dynamic, manipulable landscape rather than a static container.
- When cohesin was reduced in diseased cells, the FXN gene migrated inward and its activity measurably increased — even though the underlying DNA mutation remained entirely intact.
- The findings are preliminary but point toward a new class of therapies targeting genome organization itself, potentially bypassing the need to correct genetic mutations directly.
Inside every cell nucleus, DNA is arranged with quiet precision — chromosomes folded and positioned in three-dimensional space, with genes near the structural boundary called the nuclear lamina tending toward silence, and genes deeper inside tending toward activity. For years, scientists debated which came first: does location determine function, or function determine location? Researchers at the University of Pennsylvania's Perelman School of Medicine have now published an answer in Molecular Cell — and it is both. Gene position and gene activity are partners in continuous negotiation, adjusting one another like a dimmer rather than a simple switch.
The team focused on two key forces: transcription, the process of reading a gene into RNA, and cohesin, a protein complex that folds DNA into loops and draws distant genomic regions together. Using CRISPR tools in living cells, they showed that reducing transcription pushed genes toward the silencing edge, while amplifying cohesin did the same. Restoring transcription and dialing back cohesin reversed the movement, returning genes to the active interior. The system was not binary — it was a rheostat.
Friedreich's ataxia provided the disease lens. This rare inherited disorder devastates the nervous system and heart by silencing the FXN gene, which encodes frataxin — a protein whose absence drives the condition's progression. In patient cells, the researchers found FXN abnormally anchored at the nuclear edge, its silence seemingly reinforced by its position. When they reduced cohesin in those same cells, FXN migrated inward and its activity rose significantly — even though the causative DNA mutation remained untouched.
This is not yet a treatment, but it reframes what treatment might one day mean. If disease can be driven by where genes sit, not only by what they contain, then future therapies might work by repositioning rather than rewriting — moving a gene back into the light rather than correcting the darkness within it.
Inside the nucleus of every cell, DNA is not scattered randomly. Instead, it is arranged with deliberate precision—chromosomes folded and positioned in three-dimensional space like books on a library shelf. For decades, scientists noticed something curious: genes sitting near the nuclear edge, close to a structural boundary called the nuclear lamina, tend to stay quiet. Genes positioned deeper inside the nucleus tend to be active. But no one could say for certain which came first. Does a gene's location determine whether it works, or does its activity determine where it sits?
Researchers at the University of Pennsylvania's Perelman School of Medicine have now answered that question—and the answer is both. In work published this week in Molecular Cell, they show that gene position and gene activity are not separate forces but partners in a continuous negotiation, adjusting each other like the dial on a dimmer switch.
The team focused on two key players: transcription, the process by which a gene is read and converted into RNA, and cohesin, a protein complex that acts as a molecular origami artist, folding DNA into loops and bringing distant regions of the genome into proximity. Using CRISPR tools, the researchers systematically turned these processes up and down in living cells. When they reduced transcription, genes migrated toward the nuclear edge—the silencing zone. When they cranked up cohesin activity, genes were pushed outward and shut down. But when they restored transcription and dialed back cohesin, genes moved back inward and came alive again. The interplay was not binary. It was a continuous adjustment, a rheostat rather than a light switch.
The team chose Friedreich's ataxia as their disease model because it offered a clear window into what happens when this balance breaks. Friedreich's ataxia is a rare inherited disorder that attacks the nervous system and the heart. Its cause is brutally simple: a repeated stretch of DNA within the FXN gene—which codes for a protein called frataxin—interferes with the gene's ability to be read. The result is that frataxin levels plummet, and patients suffer devastating neurological and cardiac decline. When the researchers examined FXN in cells taken from Friedreich's ataxia patients, they found it abnormally positioned at the nuclear edge, a location that seemed to reinforce its silencing.
Then they tried something unexpected. They reduced cohesin in the diseased cells. The FXN gene moved away from the edge and back toward the nuclear interior. And as it moved, its activity increased significantly—even though the underlying DNA mutation, the repeated sequence that caused the problem in the first place, remained unchanged. The gene was not fixed. But it was working better.
This is early work, and it is not a treatment. But it points toward something larger: the possibility that disease can be driven not only by what genes we inherit but by where those genes sit and how they are organized. If that is true, then future therapies might not need to correct the mutation itself. They might simply need to reposition the gene, to move it back into a zone where it can function. For a disease as devastating as Friedreich's ataxia, even a partial restoration of gene activity could matter enormously.
Notable Quotes
Gene activity and the machinery that folds DNA work together like adjustable dials to determine where genes live inside the nucleus and whether they can function properly.— Dr. Rajan Jain, senior author of the study
Gene silencing in Friedreich's ataxia is reinforced by where the gene sits in the nucleus. By changing that positioning, we can partially restore FXN gene activity in diseased cells.— Dr. Ashley Karnay, lead author
The Hearth Conversation Another angle on the story
So the researchers found that genes have preferred neighborhoods inside the nucleus. What made them think to look at this in Friedreich's ataxia specifically?
Friedreich's ataxia was almost perfect for this question. The disease comes down to one gene being silenced—the FXN gene. But the silencing isn't caused by a simple mutation that breaks the gene's code. It's caused by a repetitive DNA sequence that interferes with how the gene is read. So there was already a mystery there: why is this gene so quiet? When they looked, they found it sitting at the nuclear edge, in the silencing zone.
And when they moved it, the gene started working again. But the mutation was still there.
Exactly. The mutation didn't go anywhere. The repeated DNA sequence is still in the gene. But by reducing cohesin—by loosening the grip of the protein that was holding the gene at the edge—they allowed the gene to move inward. And once it moved, it could be read again. It's like the gene was being held in a dark corner, and all they did was let it step into the light.
Does this mean the disease could be treated by changing gene position rather than fixing the mutation?
That's what they're suggesting, yes. But they're careful to say this is early. They've shown it's possible in cells in a dish. Whether you could do this safely in a living person, whether you could target just the right genes and not disrupt others—that's all ahead. But the principle is there. You don't always have to fix the broken thing. Sometimes you just have to move it somewhere it can work.
What about other diseases? Could this apply beyond Friedreich's ataxia?
That's the real question. If gene positioning is this important, then any disease caused by gene silencing—and there are many—might be vulnerable to this kind of approach. Neurodegenerative diseases, some cancers. The mechanism they've uncovered might be much broader than one rare disorder.